NK Cells Treatment for COVID-19

Xinxiang medical university

Status and phase: Completed; Phase 1

Conditions: Novel Coronavirus Pneumonia

Treatments: Biological: NK Cells

Study type: Interventional

Funder types: Other

Identifiers

NCT04280224

NK-COVID19

Details and patient eligibility

About

Since december 2019, acute respiratory disease due to 2019 novel coronavirus (2019-nCoV) emerged in Wuhan city and rapidly spread throughout China. There is no confirmed antivirus therapy for 2019-nCoV infection. Natural killer (NK) cells are innate lymphocytes that may serve as useful effectors against danger infection. The purpose of this clinical investigation is to evaluate the safety and efficiency of NK Cells in combination with standard therapy for pneumonia patients infected with 2019-nCoV.

Enrollment: 2 patients

Sex: All

Ages: 18 to 65 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• 1. Male or female, aged at 18 years-65 years old
• 2. Pneumonia that is judged by chest radiograph or computed tomography
• 3. Laboratory confirmation of NCP infection by reverse-transcription polymerase chain reaction(RT-PCR) from any diagnostic sampling source

Exclusion criteria

• 1. Pregnancy or breastfeeding
• 2. Known HIV, HBV or HCV infection
• 3. Patients with malignant tumor, other serious systemic diseases and psychosis
• 4. Patients who are participating in other clinical trials
• 5. Inability to provide informed consent or to comply with test requirements

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

2 participants in 2 patient groups

NK Cells Treatment Group

Experimental group

Description:

Conventional treatment plus NK cells. Participants will receive conventional treatment plus twice a week of NK cells (0.1-2\*10E7 NK cells/kg body weight).

Treatment:

Biological: NK Cells

Conventional Control Group

No Intervention group

Description:

Participants will only receive conventional treatment.